Proactive Investors - Run By Investors For Investors

Zelda Therapeutics enters German medical cannabis market with partnership

The partnership provides access to the rapidly growing German market.
gear cog with the word collaboration written on it
The partnership precedes Zelda completing various clinical trials

Zelda Therapeutics Ltd (ASX:ZLD) has entered a distribution and manufacturing strategic partnership with German medicinal cannabis group HAPA Medical.

As per the deal, HAPA will have first rights to distribute and/or manufacture Zelda’s clinically validated formulations into the rapidly growing German market. 

READ: Zelda Therapeutics strengthens Scientific and Medical Advisory Board with two appointments

Zelda’s managing director Dr Richard Hopkins said: “This partnership re-enforces the global breadth of Zelda’s relationships and shows our focus on commercialising our clinically validated formulations.

“This is also important because Germany is expected to become the world’s single largest market for medicinal cannabis.”

With a population of 83 million people, Germany is estimated to have the potential to become the world’s largest single medical cannabis market.

HAPA attracted to Zelda’s science-driven approach

HAPA’s managing director Ricardo Pendón said: “We are delighted to be entering this partnership with Zelda which is positioned as one of the world’s leading science-driven medicinal cannabis companies.

“Growth in doctor and patient use is enabled by clinically validated data and having access to Zelda’s pipeline of products is an important success factor for us.”

Zelda remains focused on rapid commercialisation of its products subject to success in clinical trials.

READ: Zelda Therapeutics attracts new managing director, Dr Richard Hopkins

Germany is a very attractive market for Zelda with legislation passed in March 2017 allowing doctors to prescribe cannabis in certain circumstances.

Furthermore, recreational use and self-cultivation are prohibited in Germany.

Cannabis-related medicines potentially reimbursable

Under the German regulatory framework, the cost of cannabis-related medicines is potentially reimbursable for patients that register with their insurer.

The subsidised nature of the medicinal cannabis industry in Germany has catalysed growth in the number of registered patients that has far exceeded initial forecasts.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

medical cannabis concept
February 11 2019
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
cannabis plant
December 15 2018
The Vancouver-based cannabis group services medical and recreational cannabis markets in Canada and internationally
A visual representation of a drug candidate working in a dog
January 29 2019
The company has reaffirmed its upcoming milestones as it confirmed December quarter achievements.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use